JP6006292B2 - インフルエンザウイルス複製を阻害するための方法および医薬組成物 - Google Patents

インフルエンザウイルス複製を阻害するための方法および医薬組成物 Download PDF

Info

Publication number
JP6006292B2
JP6006292B2 JP2014503177A JP2014503177A JP6006292B2 JP 6006292 B2 JP6006292 B2 JP 6006292B2 JP 2014503177 A JP2014503177 A JP 2014503177A JP 2014503177 A JP2014503177 A JP 2014503177A JP 6006292 B2 JP6006292 B2 JP 6006292B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
influenza
moi
infection
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014503177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510130A (ja
JP2014510130A5 (enExample
Inventor
バンサン ロットゥー
バンサン ロットゥー
シャセィ ベヌア デ
シャセィ ベヌア デ
パトリス アンドレ
パトリス アンドレ
シックリン ローレンヌ メニエル
シックリン ローレンヌ メニエル
ジェクス アンヌ オーブラン
ジェクス アンヌ オーブラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Claude Bernard Lyon 1
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Universite Claude Bernard Lyon 1 filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of JP2014510130A publication Critical patent/JP2014510130A/ja
Publication of JP2014510130A5 publication Critical patent/JP2014510130A5/ja
Application granted granted Critical
Publication of JP6006292B2 publication Critical patent/JP6006292B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014503177A 2011-04-08 2012-04-10 インフルエンザウイルス複製を阻害するための方法および医薬組成物 Expired - Fee Related JP6006292B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305410.0 2011-04-08
EP11305410 2011-04-08
PCT/EP2012/056467 WO2012136851A1 (en) 2011-04-08 2012-04-10 Methods and pharmaceutical compositions for inhibiting influenza viruses replication

Publications (3)

Publication Number Publication Date
JP2014510130A JP2014510130A (ja) 2014-04-24
JP2014510130A5 JP2014510130A5 (enExample) 2015-05-21
JP6006292B2 true JP6006292B2 (ja) 2016-10-12

Family

ID=44318127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014503177A Expired - Fee Related JP6006292B2 (ja) 2011-04-08 2012-04-10 インフルエンザウイルス複製を阻害するための方法および医薬組成物

Country Status (6)

Country Link
US (1) US9168236B2 (enExample)
EP (1) EP2694046A1 (enExample)
JP (1) JP6006292B2 (enExample)
KR (1) KR20140027987A (enExample)
CN (1) CN103648491B (enExample)
WO (1) WO2012136851A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR200469630Y1 (ko) 2012-10-29 2013-10-28 태영주식회사 폐합성수지의 재활용을 위한 세척장치
KR102251682B1 (ko) * 2020-09-08 2021-05-17 주식회사 알엠 폐플라스틱 페트류 및 페트 플레이크의 세정 및 살균 방법

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015124570A1 (en) * 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of influenza a virus infection
US10413552B2 (en) 2015-06-18 2019-09-17 The Hospital For Sick Children Method of treating medulloblastoma
CN108712905B (zh) * 2016-03-11 2022-02-08 国立大学法人鹿儿岛大学 抗肝肿瘤病毒剂
CN113197894B (zh) * 2020-02-02 2022-08-05 武汉大学 奥巴托克在制备广谱抗冠状病毒药物中的应用
CN114796215B (zh) * 2022-05-27 2023-07-07 贵州医科大学 替罗非班在用于制备治疗人呼吸道合胞病毒感染的药物中的应用
WO2024054941A1 (en) * 2022-09-08 2024-03-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for inhibiting viral methyltransferases
CN116549460A (zh) * 2023-03-23 2023-08-08 大连大学 糖类皮质激素在制备预防和治疗病毒性上呼吸道疾病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258585B1 (en) 1992-05-14 2001-07-10 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting influenza virus replication
JP4578578B2 (ja) * 1997-01-13 2010-11-10 エモリー、ユニバーシティ インフルエンザ感染の治療用化合物及びそれらの組み合わせ
US6455571B1 (en) 1998-04-23 2002-09-24 Abbott Laboratories Inhibitors of neuraminidases
CN100411617C (zh) * 2000-07-28 2008-08-20 伊穆法姆公司 黄酮类化合物制备药物的用途
US20050170334A1 (en) 2002-03-13 2005-08-04 Toshifumi Mikayama Human monoclonal antibodies to influenza M2 protein and methods of making and using same
PT1644363E (pt) * 2003-05-30 2012-05-18 Gemin X Pharmaceuticals Canada Inc Compostos tri-heterocíclicos, composições e métodos para tratamento de cancro ou doenças virais
WO2006029081A2 (en) * 2004-09-02 2006-03-16 Neopharm, Inc. Nucleoside-lipid conjugates, their method of preparation and uses thereof
US20070270362A1 (en) * 2006-05-18 2007-11-22 The University Of Washington Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders
US9289462B2 (en) * 2008-09-17 2016-03-22 Terry Gage Method for medical treatment utilizing glutathione
CA2739765A1 (en) * 2008-10-08 2010-04-15 Vincent Serra Vaccine composition for use against influenza
CA2746256C (en) * 2008-12-09 2020-03-24 Loren D. Walensky Methods and compositions for specific modulation of mcl-1
WO2010101663A2 (en) * 2009-03-06 2010-09-10 Mount Sinai School Of Medicine Of New York University Live attenuated influenza virus vaccines comprising microrna response elements
JP2013506682A (ja) * 2009-09-30 2013-02-28 セント ルイス ユニバーシティ 異種亜型インフルエンザｔ細胞応答を誘発するためのペプチド

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR200469630Y1 (ko) 2012-10-29 2013-10-28 태영주식회사 폐합성수지의 재활용을 위한 세척장치
KR102251682B1 (ko) * 2020-09-08 2021-05-17 주식회사 알엠 폐플라스틱 페트류 및 페트 플레이크의 세정 및 살균 방법

Also Published As

Publication number Publication date
US9168236B2 (en) 2015-10-27
EP2694046A1 (en) 2014-02-12
JP2014510130A (ja) 2014-04-24
US20140030224A1 (en) 2014-01-30
CN103648491A (zh) 2014-03-19
KR20140027987A (ko) 2014-03-07
WO2012136851A1 (en) 2012-10-11
CN103648491B (zh) 2017-07-14

Similar Documents

Publication Publication Date Title
JP6006292B2 (ja) インフルエンザウイルス複製を阻害するための方法および医薬組成物
Hayden Developing new antiviral agents for influenza treatment: what does the future hold?
JP6294889B2 (ja) ウイルス疾患の処置におけるｍｅｋ阻害物質
JP6567781B2 (ja) ウイルス感染症の治療用チアゾリド化合物
JP2023526547A (ja) 気道粘膜におけるウイルス複製を低下させるための特定の薬物のシステム、方法、及び使用
CN111467363A (zh) 索非布韦在制备预防和治疗冠状病毒的药物中的应用
CN111407754A (zh) 卡谷氨酸在制备预防和治疗冠状病毒的药物中的应用
Cheer et al. Zanamivir: an update of its use in influenza
US20180185404A1 (en) Compositions and methods for the treatment of viral infection
JP2021516219A (ja) ライノウイルス感染症の予防又は治療のための薬物
CN111420024A (zh) 杆菌酞a在制备预防和治疗冠状病毒的药物中的应用
US11433080B2 (en) Antiviral treatment
CN111467355A (zh) 膦甲酸钠在制备预防和治疗冠状病毒的药物中的应用
US20190298669A1 (en) Ci-1040 for the treatment of viral diseases
Arruda et al. Update on therapy of influenza and rhinovirus infections
US20230149429A1 (en) Use of a nitrogen-containing bisphosphonate in combination with a glucocorticoid in preventing or treating viral pneumonia
RU2842052C1 (ru) Азеластин в качестве противовирусного лечения
Gökçe et al. An overview of COVID-19 medicines in current guidelines
US20210346459A1 (en) Application of Dalargin for the prevention of VRIs and prevention of the development of complications during VRIs
CA2999670A1 (en) Ci-1040 for the treatment of viral diseases
Dharmaraj et al. World Journal of Biology Pharmacy and Health Sciences
AU2018202283A1 (en) Ci-1040 for the treatment of viral diseases
WO2022049414A1 (es) Nitazoxanida para su uso en el tratamiento de covid-19
Creer et al. Treatment of common colds
CN114432305A (zh) Cay10603在制备预防和治疗冠状病毒的药物中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131107

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20131106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160908

R150 Certificate of patent or registration of utility model

Ref document number: 6006292

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees